Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Naltrexone
Drug ID BADD_D01527
Description Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Indications and Usage Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
Marketing Status approved; investigational; vet_approved
ATC Code N07BB04
DrugBank ID DB00704
KEGG ID D05113
MeSH ID D009271
PubChem ID 5360515
TTD Drug ID D0PG8O
NDC Product Code 16447-0689; 69641-0002; 82105-003; 0406-3940; 65757-300; 0406-4605; 43798-006; 65757-360; 65757-301
UNII 5S6W795CQM
Synonyms Naltrexone | Antaxone | Trexan | EN-1639A | EN 1639A | EN1639A | ReVia | Nemexin | Nalorex | Naltrexone Hydrochloride | Celupan
Chemical Information
Molecular Formula C20H23NO4
CAS Registry Number 16590-41-3
SMILES C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abortion missed18.01.01.002--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.04.005--
Alcohol abuse19.07.06.001--Not Available
Alcoholism19.07.06.006--Not Available
Alopecia23.02.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angina unstable24.04.04.004; 02.02.02.004--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aortic dissection24.02.03.002--Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.011--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Aspartate aminotransferase abnormal13.03.04.009--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Blood creatine phosphokinase abnormal13.04.01.002--Not Available
Blood creatinine normal13.13.01.021--Not Available
Blood pressure fluctuation24.06.01.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature increased13.15.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene